Prescribing of sulfasalazine, azathioprine and methotrexate round pregnancy - A descriptive study

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 1, 2008, Pages 52-61

  Vroom, Fokaline ^a   van Roon, Eric N ^a,b   van den Berg, Paul B ^a   Brouwers, Jacobus R B J ^a,b   de Jong van den Berg, Lolkje T W ^a,c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b MEDICAL CENTER LEEUWARDEN   (Netherlands)

^c Antonius Deusinglaan 1   (Netherlands)

Author keywords

Azathioprine; Drug therapy; Methotrexate; Pregnancy; Sulfasalazine

Indexed keywords

ANTIDIARRHEAL AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIPYRETIC AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CHLOROQUINE; CODEINE; CORTICOSTEROID; CYCLOSPORIN; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GASTROINTESTINAL AGENT; HYDROXYCHLOROQUINE; IBUPROFEN; IMMUNOSUPPRESSIVE AGENT; INDOMETACIN; LAXATIVE; LOPERAMIDE; MELOXICAM; METHOTREXATE; NAPROXEN; NARCOTIC ANALGESIC AGENT; OPIATE DERIVATIVE; PARACETAMOL; PIROXICAM; PREDNISOLONE; SALAZOSULFAPYRIDINE; UNINDEXED DRUG;

ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; DATA BASE; DESCRIPTIVE RESEARCH; DRUG WITHDRAWAL; ENTERITIS; FEMALE; FETUS RISK; HUMAN; MALARIA; NETHERLANDS; PHARMACY; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATIC DISEASE;

ANTIRHEUMATIC AGENTS; AZATHIOPRINE; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; METHOTREXATE; PHYSICIAN'S PRACTICE PATTERNS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTERS; PRESCRIPTIONS, DRUG; RHEUMATIC DISEASES; RISK FACTORS; SULFASALAZINE;

EID: 38649138819     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1506     Document Type: Article

References (28)

1. Knigge KL. Inflammatory bowel disease. Clin Cornerstone 2002; 4: 49-60.
2. Connell W, Miller A. Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy. Drug Saf 1999; 21: 311-323.
3. [no authors listed]. Guidelines for the management of rheumatoid arthritis. American College of Rheurnatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996; 39: 713-722.
4. [no authors listed]. Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996; 39: 723-731.
5. Ostensen M, Ramsey-Goldman R. Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options? Drug Saf 1998; 19(5): 389-410.
6. Lacroix I, Damase-Michel C, Lapeyre-Mestre M, et al. Prescription of drugs during pregnancy in France. Lancet 2000; 356:1735-1736.
7. Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004; 191: 398-407.
8. Czeizel AE. Drug use during pregnancy. Lancet 2001; 357:800.
9. Egen-Lappe V, Hasford J. Drug prescription in pregnancy: analysis of a large statutory sickness fund population. Eur J Clin Pharmacol 2004; 60: 659-666.
10. Headley J, Northstone K, Simmons H, et al. Medication use during pregnancy: data from the Avon Longitudinal Study of Parents and Children. Eur J Clin Pharmacol 2004; 60: 355-361.
11. Bakker MK, Jentink J, Vroom F, et al. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG 2006; 113: 559-568.
12. Gur C, av-Citrin O, Shechtman S, et al. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol 2004; 18: 93-101.
13. De Santis M, Straface G, Cavaliere A, et al. Paternal and maternal exposure to leflunomide: pregnancy and neonatal outcome. Ann Rheum Dis 2005; 64: 1096-1097.
14. Fernandez M, Andrade R, Alarcon GS. Cyclophosphamide use and pregnancy in lupus. Lupus 2006; 15: 59.
15. Li DK, Liu L, Odouli R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ 2003; 327: 368.
16. Leufkens HGM, Urquhart J. Automated Pharmacy Record Linkage in the Netherlands. In Pharmacoepidemiology Storm BL (ed.) (3rd edn). John Wiley, Chichester 2000; 347-360.
17. [no authors listed]. WHO Collaborating Centre for drug Statistics Methodology www.whocc.no/atcddd/. (Accessed 18 Sep 2006).
18. Schirm E, Tobi H, de Jong-van den Berg LT. Identifying parents in pharmacy data: a tool for the continuous monitoring of drug exposure to unborn children. J Clin Epidemiol 2004; 57: 737-741.
19. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation, (6th edn). Lippincott Williams & Wilkins, Philadelphia. 2002.
20. Vroom F, de Walle HEK, van der Laar MAJF, et al. Disease-modifying antirheumatic drugs in pregnancy. Current status and implications for the future. Drug Saf 2006; 29: 845-863.
21. Norgard B, Pedersen L, Fonager K, et al. Azathioprine, mercaptopurine and birth outcome: a population-based cohort study. Aliment Pharmacol Ther 2003; 17: 827-834.
22. Temprano KK, Bandlamudi R, Moore TL. Antirheumatic drugs in pregnancy and lactation. Semin Arthritis Rheum 2005; 35: 112-121.
23. Ferrero S, Ragni N. Inflammatory bowel disease: management issues during pregnancy. Arch Gynecol Obstet 2004; 270: 79-85.
24. Diav-Citrin O, Park YH, Veerasuntharam G, et al. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology 1998; 114: 23-28.
25. de Boer NK, Jarbandhan SV, de Graaf P, et al. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol 2006; 101: 1390-1392.
26. Olesen C, Sondergaard C, Thrane N, et al. Do pregnant women report use of dispensed medications? Epidemiology 2001; 12: 497-501.
27. Malm H, Martikainen J, YJaukka T, et al. Prescription drugs during pregnancy and lactation - a Finnish register-based study. Eur J Clin Pharmacol 2003; 59: 127-133.
28. Raebel MA, Ellis JL, Andrade SE. Evaluation of gestational age and admission date assumptions used to determine prenatal drug exposure from administrative data. Pharmacoepidemiol Drug Saf 2005; 14: 829-836.